Hepatitis C Management in Special Populations
Summary
- Drug–drug interactions between HCV therapy and ART is the primary consideration when selecting DAA therapy in HCV/HIV-coinfected patients
- The AASLD/IDSA and EASL provide recommendations on the use of certain HCV therapies with ART (Table 11)
- Sofosbuvir is a substrate for P-gp and BCRP; should not be coadministered with potent P-gp inducers such as rifampin or St John’s wort[FDA Sofosbuvir]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C, Hepatitis C-Special Populations